The dose and administration of nivolumab will be performed in accordance with directions 147 in the package insert: 240 mg every 2 weeks by intravenous drip infusion. Administration 148 of nivolumab will be continued until one of the following endpoints is reached: radiological 149 or clinical disease progression, participant death, occurrence of grade ≥ 3 adverse events, 150 prolonged development of adverse events above grade 1 severity, or participant refusal. 151 As indicated in the package insert, there will be a delay of ≥ 7 days from the 152 discontinuation of pretreatment until the start of nivolumab administration. There will be 153 no provision for post-treatment medications. Case registration and allocation 161 1) A clinical physician involved in the study will perform a screening test within 7 days 162 after acquiring informed consent from a potential subject, in order to determine the 163 subject's eligibility. 164 2) If eligibility is confirmed, the clinical physician will promptly use the case registration 165 application form to record the subject's identification code, sex, age, date of consent, and 166 scheduled administration start date; this form will be submitted to the secretariat. 3) The research secretariat will record drug assignment and provide a confirmation letter The researchers will preserve samples for 5 years from the date reported on the final 179 public announcement of the results of this study. Samples will then be discarded in a 180 manner that avoids identification of the subjects'. The sample and information obtained 181 will not be used for purposes other than this study. Provision of samples and information 182 to other institutions will be prohibited.
184
Data management 185 The clinical physicians will confirm that each potential subject meets the inclusion criteria 186 and will complete corresponding registration forms. Each subject will be assigned an 187 identification code when their registration form is submitted to the research executive 188 office. The research director will prepare a coded list to facilitate the identification of 189 subjects during and after the research. As necessary, the clinical physicians will confirm 190 the validity of this document. The code list confidentiality will be maintained, and the 191 research director will retain the list in the research file. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Planned statistical analysis of baseline characteristics 204 The distribution of participant baseline characteristics in each group will be described by 205 summary statistics, such as median and frequency. Differences between groups of 206 patients will be tested with a two-tailed Student's t-test of medians for quantitative 207 variables; differences between groups of patients will be tested with a chi-squared test of 208 distributions for categorical variables. Differences in adverse events between two groups 209 will be tested with Fisher's exact test.
211
Planned statistical analysis of primary endpoints 212 Progression-free intervals will be estimated by the Kaplan-Meier method, and the 213 resulting distribution will be compared using a log-rank test. Differences will be regarded 214 as statistically significant at P < 0.05.
216
Planned statistical analysis of secondary endpoints 217 Secondary endpoints will be analysed to supplement assessment of the primary endpoint.
218
The response rate will analysed using the chi-squared test. The percentage difference 219 and its 95% confidence interval will be estimated. Overall survival will be estimated by 220 the Kaplan-Meier method, and the resulting distribution will be compared using a log-221 rank test. Differences will be regarded as statistically significant at P < 0.05.
223

Analysis of safety 224
Adverse events will be summarized by using frequency and percentage, and a summary 225 In prior studies, sPD-L1 was reported to exhibit a positive correlation with the 243 aggressiveness of RCC. Therefore, we hypothesize that in patients with high serum-244 soluble PD-L1 concentration, the therapeutic effect of nivolumab will be greater.
245
This study is a single-arm, exploratory clinical trial, which may be a limitation. With this 246 study design, treatment bias cannot be completely excluded. Moreover, in terms of 247 comparison between groups, it is difficult to ensure that patients have similar 248 backgrounds.
249
In conclusion, there have been few prospective studies of predictive biomarkers for the 250 effectiveness of nivolumab. Thus, a prospective study is needed to determine the 251 feasibility and efficacy of sPD-L1. Subjects in Japan, and the Clinical Trial Act in Japan. Findings of this study will be widely 257 disseminated through conference presentations, reports, factsheets, and academic 258 publications; further generalisations will also be discussed.
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161
As indicated in the package insert, there will be a delay of ≥ 7 days from the 162 discontinuation of pretreatment until the start of nivolumab administration. There will be 163 no provision for post-treatment medications. There will be no provision for post-treatment 164 medications, except for treatment to occurrence of adverse events. 2) If eligibility is confirmed, the subject will be registered and the clinical physician will 176 promptly use the case registration application form to record the subject's identification 177 code, sex, age, date of consent, and scheduled administration start date; this form will 178 be submitted to the secretariat. The clinical physicians will confirm that each potential subject meets the inclusion criteria 198 and will complete corresponding registration forms. Each subject will be assigned an 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Planned statistical analysis of baseline characteristics 216 The distribution of participant baseline characteristics in each group will be described by 217 summary statistics, such as median and frequency. Differences between groups of 218 patients will be tested with the Wilcoxon rank-sum test for quantitative variables; 219 differences between groups of patients will be tested with chi-squared test for categorical 220 variable variables. Differences in adverse events between two groups will be tested with
221
Fisher's exact test.
223
Planned statistical analysis of primary endpoints 224 Progression-free survivals will be estimated by the Kaplan-Meier method, and the 225 resulting distribution will be compared using a log-rank test. Differences will be regarded 226 as statistically significant at P < 0.05.
228
Planned statistical analysis of secondary endpoints 229 Secondary endpoints will be analysed to supplement assessment of the primary endpoint.
230
The response rate will analysed using the chi-squared test. The percentage difference 231 and its 95% confidence interval will be estimated. Overall survival will be estimated by 232 the Kaplan-Meier method, and the resulting distribution will be compared using a log-233 rank test. Differences will be regarded as statistically significant at P < 0.05.
235
Analysis of safety 236 Adverse events will be summarized by using frequency and percentage, and a summary 237 table will be prepared. The analysis of safety will be performed for the subjects that 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Monitoring will be performed periodically to ensure that this research is carried out safely 242 and in accordance with the implementation plan, as well as to determine whether data 243 are accurately recorded and stored. This work will be supervised by dedicated staff 244 members.
Patient and Public Involvement
247
Patients and public were not involved in the design of this study. Moreover, they will not 248 be involved in the recruitment to the study, nor the conduct of the study. 
254
In prior studies, sPD-L1 was reported to exhibit a positive correlation with the 255 aggressiveness of RCC. Therefore, we hypothesize that in patients with high serum-256 soluble PD-L1 concentration, the therapeutic effect of nivolumab will be greater.
257
This study is a single-arm, exploratory clinical trial, which may be a limitation. With this 258 study design, treatment bias cannot be completely excluded. Moreover, in terms of 259 comparison between groups, it is difficult to ensure that patients have similar 260 backgrounds.
261
In conclusion, there have been few prospective studies of predictive biomarkers for the 262 effectiveness of nivolumab. Thus, a prospective study is needed to determine the 263 feasibility and efficacy of sPD-L1. Subjects in Japan, and the Clinical Trial Act in Japan. Findings of this study will be widely 269 disseminated through conference presentations, reports, factsheets, and academic 270 publications; further generalisations will also be discussed.
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